Effect of interaction between acute administration of morphine and cannabinoid compounds on spontaneous excitatory and inhibitory postsynaptic currents of magnocellular neurons of supraoptic nucleus

Document Type: Original Article

Authors

1 Department of Physiology, Faculty of Medicine, Artesh University of Medical Science, Tehran, Iran

2 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 Neuroscience Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran

4 Department of Physiology, Faculty of Medicine, Shahid Beheshti University of Medical Science, Tehran, Iran

Abstract

Objective(s): Opioids and cannabinoids are two important compounds that have been shown to influence the activity of magnocellular neurons (MCNs) of supraoptic nucleus (SON). The interaction between opioidergic and cannabinoidergic systems in various structures of the brain and spinal cord is now well established, but not in the MCNs of SON.
Materials and methods: In this study, whole cell patch clamp recording of neurons in rat brain slice was used to investigate the effect of acute morphine and cannabinoid administration on spontaneous inhibitory and excitatory spostsynaptic currents (sIPSCs and sEPSCs) in MCNs.
Results: Bath application of morphine produced an increase in sEPSCs frequency and a decrease in sIPSCs frequency. In contrast, bath application of URB597 (fatty acid amide hydrolase (FAAH) inhibitor) produced a decrease in sEPSCs frequency but an increase in sIPSCs frequency. WIN55212-2 (cannabinoid receptor agonist) decreased both sIPSCs and sEPSCs frequencies of MCNs. Co-application of morphine and URB597 attenuated the effect of morphine on MCNs.
Conclusion: Taken together, these data indicated that at the cellular level, pharmacological augmentation of endocannabinoids could attenuate morphine effects on MCNs.

Keywords


1. Mircić GM, Beleslin DB, Janković SM. Hormones of the posterior region of the hypophyseal gland. Srp Arh Celok Lek 1998; 126:111-118.

2. Aoyagi T, Izumi Y, Hiroyama M, Matsuzaki T, Yasuoka Y, Sanbe A, et al. Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells. Am J Physio Renal Physiol 2008; 295:100-107.

3. Smith AM, Elliot CM, Kiely DG, Channer KS. The role of vasopressin in cardiorespiratory arrest and pulmonary hypertension. Q J Med 2006; 99:127–133.

4. Van den Pol AN, Wuarin JP, Dudek FE. Glutamate, the dominant excitatory transmitter in neuroendocrine regulation. Science 1990; 250:1276–1278.

5. Van den Pol AN, Trombley PQ. Glutamate neurons in hypothalamus regulate excitatory transmission. J Neurosci 1993; 13:2829–2836.

6. Decavel C, Van den Pol AN. GABA: a dominant neurotransmitter in the hypothalamus. J Comp Neurol 1990; 302:1019-1037.

7. El Majdoubi M, Poulain DA, Theodosis DT. Lactation-induced plasticity in the supraoptic nucleus augments axodendritic and axosomatic GABAergic and glutamatergic synapses: an ultrastructural analysis using the disector method. Neuroscience 1997; 80:1137-1147.

8. Ludwig M, Pittman QJ. Talking back: dendritic neurotransmitter release. Trends Neurosci 2003; 26: 255–261.

9. Morris JF, Ludwig M. Magnocellular dendrites: prototypic receiver/transmitters. J Neuroendocrinol 2004; 16:403–408.

10. Doi N, Brown CH, Cohen HD, Leng G, Russell JA. Effects of the endogenous opioid, endomorphin 1, on supraoptic nucleus oxytocin and vasopressin neurons in vivo and in vitro. Br J Pharmacol 2001; 132:1136-1144.

11. Di S, Boudaba C, Popescu IR, Weng FJ, Harris C, Marcheselli VL, et al. Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. J Physiol 2005; 569:751–760.

12. Di S, Malcher-Lopes R, Marcheselli VL, Bazan NG, Tasker JG. Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and γ-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 2005; 145:4292–4301.

13. Hirasawa M, Schwab Y, Natah S, Hillard CJ, Mackie K, Sharkey KA, et al. Dendritically released transmitters cooperate via autocrine and retrograde actions to inhibit afferent excitation in rat brain. J Physiol 2004; 559:611-624.

14. Liu QS, Han S, Jia YS, Ju G. Selective modulation of excitatory transmission by mu-opioid receptor activation in rat supraoptic neurons. J Neurophysiol 1999; 82:3000-3005.

15. Wakerley JB, Noble R, Clarke G. Effects of morphine and D-Ala, D-Leu enkephalin on the electrical activity of supraoptic neurosecretory cells in vitro. Neuroscience 1983; 10:73-81.

16. Koyuncuoğlu H, Berkman K, Hatipoğlu I, Sabuncu H. Vasopressin release by D-aspartic acid, morphine and prolyl-leucyl-glycinamide (PLG) in DI Brattleboro rats. Pharmacol Biochem Behav 1984; 20:519-525.

17. Korinek AM, Languille M, Bonnet F, Thibonnier M, Sasano P, Lienhart A, et al. Effect of postoperative extradural morphine on AVP secretion. Br J Anaesth 1985; 57:407-411.

18. Philbin DM, Wilson NE, Sokoloski J, Coggins C. Radioimmunoassay of antidiuretic hormone during morphine anaesthesia. Can Anaesth Soc J 1976; 23:290-295.

19. Robertson SA, Hauptman JG, Nachreiner RF, Richter MA. Effects of acetylpromazine or morphine on urine production in halothane-anesthetized dogs. Am J Vet Res 2001; 62:1922-1927.

20. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 1999; 20:287–294.

21. Massi P, Vaccani A, Romorini S, Parolaro D. Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects. J Neuro-immunol 2001; 117:116–124.

22. Childers SR, Fleming L, Konkoy C, Marckel D, Pacheco M, Sexton T. Opioid and cannabinoid receptor inhibition of adenylyl cyclase

23. Yousefpour M, Naderi N, Mansouri Z, Janahmadi M, Alizadeh AM, Motamedi F. The Comparison of the Effects of Acute and Repeated Morphine Administration on Fast Synaptic Transmission in Magnocellular Neurons of Supraoptic Nucleus, Plasma Vasopressin Levels, and Urine Volume of Male Rats. Iran J Pharm Res 2014; 13:975-985.

24. Brussaard AB, Kits KS, De Vlieger TA. Postsynaptic mechanism of depression of GABAergic synapses by oxytocin in the supraoptic nucleus of immature rat. J Physiol 1996; 497:495-507.

25. Chang SL, Patel NA, Romero AA, Thompson J, Zadina JE. FOS expression induced by interleukin-1 or acute morphine treatment in the rat hypothalamus is attenuated by chronic exposure to morphine. Brain Res 1996; 736:227-236.

26. Muller W, Hallermann S, Swandulla D. Opioidergic modulation of voltage-activated K1currents in magno-cellular neurons of the supraoptic nucleus in rat. J Neurophysiol 1999; 81:1617-1625.

27. Di S, Halmos K, Tasker JG. Cannabinoid regulation of synaptic inputs to hypothalamic neuroendocrine cells. Program No. 612.12. Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience; 2003. Online

28. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003; 83:1017–1066.

29. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994; 372:686–691.

30. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997; 388:773–778.

31. Béquet F, Uzabiaga F, Desbazeille M, Ludwiczak P, Maftouh M, Picard C, et al. CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus. Eur J Neurosci 2007; 26:3458-3464.

32. Solinas M, Goldberg SR.  Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems. Neuropsychopharmacology 2005; 30:2035–2045.

33. Hajos N, Ledent C, Freund TF. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuro-science 2001; 106:1–4.

34. Wenger T, Ledent C, Tramu G. The endogenous cannabinoid, anandamide, activates the hypo-thalamo-pituitary-adrenal axis in CB1 cannabinoid receptor knockout mice. Neuroendocrinology 2003; 78:294-300.

35. Sawzdargo M, Nguyen T, Lee DK, Lynch KR, Cheng R, Heng HH, et al.  Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 1999; 64:193-198.

36. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152:1092-1101.

37. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharm Rev 2002; 54:161-202.

38. Garzón J, de la Torre-Madrid E, Rodríguez-Muñoz M, Vicente-Sánchez A, Sánchez-Blázquez P. Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine. Mol Pain 2009; 10:5-11.

39. Tanda G, Goldberg SR. Cannabinoids: reward, dependence, and underlying neurochemical mecha-nisms, a review of recent preclinical data. Psychophar-macology 2003; 169:115–134.

40. Valverde O, Noble F, Beslot F, Dauge V, Fournie-Zaluski MC, Roques BP. Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci 2001; 13:1816–1824.

41. Solinas M, Zangen A, Thiriet N, Goldberg SR. Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of delta-9-tetrahydro-cannabinol. Eur J Neurosci 2004; 19:3183–3192.

42. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346:561–564.

43. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283:401–404.

44. Mascia MS, Obinu MC, Ledent C, Parmentier M, Bohme GA, Imperato A. Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB (1) receptor knockout mice. Eur J Pharmacol 1999; 383:R1–R2.

45. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 2000; 12:4038–4046.

46. Cossu G, Ledent C, Fattore L, Imperato A, Bohme GA, Parmentier M. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 2001; 118: 61–65.

47. De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 2001; 7:1151–1154.

48. Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR. The cannabinoid CB1 antagonist                               N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichloro-phenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differen-

tially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharm Exp Ther 2003; 306:93–102.

49. Vigano D, Cascio MG, Rubino T, Fezza F, Vaccani A, Marzo VD, et al. Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. Neuropsychopharmacology 2003; 28:1160–1167.

50. Gonzalez S, Schmid PC, Fernandez-Ruiz J, Krebsbach R, Schmid HH, Ramos JA. Region-dependent changes in endocannabinoid transmission in the brain of morphine-dependent rats. Addict Biol 2003; 8:159–166.

51. Vigano D, Valenti M, Cascio MG, Di Marzo V, Parolaro D. Changes in endocannabinoid levels in a rat model of behavioral sensitization to morphine. Eur J Neurosci 2004; 20:1849–1857.

52. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J Neurosci 1987; 7:2445–2464.

53. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991; 11:563–583.

54. Rodriguez JJ, Mackie K, Pickel VM. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci 2001; 21:823–833.

55. Reisine T, Law SF, Blake A, Tallent M. Molecular mechanisms of opiate receptor coupling to G proteins and effector systems. Ann N Y Acad Sci 1996; 780:168–175.

56. Azizi P, Haghparast A, Hassanpour-Ezatti M. Effects of CB1 receptor antagonist within the nucleus accum-bens on the acquisition and expression of morphine-induced conditioned place preference in morphine-sensitized rats. Behav Brain Res 2009; 197:119-124.